SYNERGISM OF CYTOTOXICITY BETWEEN CIS-DIAMINEDICHLORO-PLATINUM-(II) AND CIS-DIAMINE(1,1-CYCLOBUTANEDICARBOXYLATE)-PLATINUM-(II)
- H BABA
- Y MAEHARA
- H TAKEUCHI
- S INUTSUKA
- M YAMAMOTO
- K ENDO
- K SUGIMACHI
Affiliations: KYUSHU UNIV,FAC MED,CTR CANC,FUKUOKA 812,JAPAN. KYUSHU UNIV,FAC MED,DEPT SURG 2,FUKUOKA 812,JAPAN.
- Published online on: February 1, 1994 https://doi.org/10.3892/ijo.4.2.329
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
In an attempts to increase the antitumor effect and to reduce normal tissue toxicity, the combined cytotoxic effect of cis-Diamminedichloroplatinum (II) (CDDP) and cis-diammine(1,1-cyclobutane dicarboxylate) platinum (II) (CBDCA) was investigated using HeLa and colon 26 cell lines and the combination index (CI). Cytotoxicity of the combination of CDDP and CBDCA on 27 surgically resected specimens of human gastric and colorectal adenocarcinomas was also evaluated using the in vitro succinate dehydrogenase inhibition (SDI) test. The CI values varied with the dose ratio examined (1:1-1:6) of CDDP and CBDCA, with findings that CI<1, synergy, was obtained at fraction affected (Fa)>0.75 for HeLa cells and at Fa<0.9 for colon 26 cells in cases of a dose ratio of 1:1 to 1:2. Of all 27 clinical human adenocarcinomas, the succinate dehydrogenase (SD) activity was significantly lower in cancer cells concomitantly exposed to both CDDP and CBDCA than in those exposed to either drug alone. These positive effects of a combination of two platinum analogues on human malignant tissues have heretofore not been reported, which would warrant the clinical application of this combination for human malignant tumors.